Phibro Animal Health Corporation (PAHC)
(Delayed Data from NSDQ)
$22.62 USD
-0.21 (-0.92%)
Updated Mar 5, 2021 04:00 PM ET
After-Market: $22.68 +0.06 (0.27%) 7:00 PM ET
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
| Zacks Rank | Definition | Annualized Return |
|---|---|---|
| 1 | Strong Buy | 24.41% |
| 2 | Buy | 17.88% |
| 3 | Hold | 9.48% |
| 4 | Sell | 5.03% |
| 5 | Strong Sell | 1.87% |
| S&P | 500 | 10.70% |
Zacks Rank Education - Learn about the Zacks Rank
Zacks Rank Home - Zacks Rank resources in one place
Zacks Premium - The only way to fully access the Zacks Rank
3-Hold of 5 3
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
| Value Score | A |
|---|---|
| Growth Score | A |
| Momentum Score | A |
| VGM Score | A |
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Style Scores Education - Learn more about the Zacks Style Scores
A Value B Growth C Momentum A VGM
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank
View All Zacks #1 Ranked Stocks
Zacks News
Why Is Phibro (PAHC) Up 1.1% Since Last Earnings Report?
by Zacks Equity Research
Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PAHCNegative Net Change
earnings earnings-estimates earnings-performance earnings-report earnings-trend revenue zacks-consensus-estimate
PAHC or RMD: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PAHC vs. RMD: Which Stock Is the Better Value Option?
PAHCNegative Net Change RMDPositive Net Change
value-stocks which-stock-is-cheaper
Phibro (PAHC) Q2 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Phibro's (PAHC) second-quarter revenue declined 3.7% year over year to $206.1 million and gross profit improved 33%.
ANGOPositive Net Change ABTPositive Net Change PAHCNegative Net Change NXGNPositive Net Change
earnings medical
PAHC vs. SRDX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PAHC vs. SRDX: Which Stock Is the Better Value Option?
PAHCNegative Net Change SRDXPositive Net Change
value-stocks which-stock-is-cheaper
Phirbo (PAHC) Nutritional Specialty Aids Growth, Low ASP Ails
by Zacks Equity Research
Phirbo's (PAHC) net vaccine sales remain robust on higher international demand for poultry vaccines.
AMEDPositive Net Change PDCOPositive Net Change IDXXPositive Net Change PAHCNegative Net Change
medical
Why Is Phibro (PAHC) Up 1.4% Since Last Earnings Report?
by Zacks Equity Research
Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PAHCNegative Net Change
earnings earnings-estimates earnings-performance earnings-report earnings-trend revenue zacks-consensus-estimate
Phibro (PAHC) Hurt by Adverse Pricing in Mineral Nutrition Arm
by Zacks Equity Research
Lower sales of Phibro's (PAHC) Performance Products arm's copper-based products raise concerns.
RMDPositive Net Change ALGNPositive Net Change TMOPositive Net Change PAHCNegative Net Change
medical
Phibro (PAHC) Q1 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Phibro's (PAHC) core Animal Health segment, along with strength in Nutritional Specialties and Vaccines, boosted Q1 performance despite pandemic-led business disruptions.
ALGNPositive Net Change TMOPositive Net Change WSTPositive Net Change PAHCNegative Net Change
earnings medical
PAHC vs. RMD: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PAHC vs. RMD: Which Stock Is the Better Value Option?
PAHCNegative Net Change RMDPositive Net Change
value-stocks which-stock-is-cheaper
Why Is Phibro (PAHC) Down 14.8% Since Last Earnings Report?
by Zacks Equity Research
Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PAHCNegative Net Change
earnings earnings-estimates earnings-performance earnings-report earnings-trend revenue zacks-consensus-estimate
Phirbo's Product Mix Aids, Global Animal Health Business Ails
by Zacks Equity Research
Phirbo (PAHC) catered industries face issues like lack of processing availability and sudden drop in demand.
HOLXPositive Net Change QGENNegative Net Change TMOPositive Net Change PAHCNegative Net Change
medical
Phibro (PAHC) Q4 Earnings Fall Short of Estimates, Margins Up
by Zacks Equity Research
Phibro's (PAHC) core Animal Health segment was aided by the Osprey Biotechnics acquisition despite a dismal overall performance in Q4 due to pandemic-led business disruptions.
HOLXPositive Net Change TMOPositive Net Change WSTPositive Net Change PAHCNegative Net Change
earnings medical
Phibro (PAHC) Q3 Earnings Surpass Estimates, Margin Declines
by Zacks Equity Research
Phibro (PAHC) witnessed revenue uptick in its core Animal Health segment in Q3 despite the coronavirus-led business disruptions in the animal production industry.
BIIBPositive Net Change LLYPositive Net Change PAHCNegative Net Change APHANegative Net Change
earnings medical
Here's Why You Should Add Tandem Diabetes to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Tandem Diabetes (TNDM) on its strength in the diabetes business and receipt of regulatory approvals.
RMDPositive Net Change PAHCNegative Net Change TNDMPositive Net Change EYEPositive Net Change
Walgreens' Retail Pharmacy Grows Amid Coronavirus Crisis
by Zacks Equity Research
Walgreens (WBA) registers growing demand for Retail Pharmacy & Pharmaceutical Wholesale products in Q2.
RMDPositive Net Change PAHCNegative Net Change WBAPositive Net Change EYEPositive Net Change
medical
Abbott Launches Antibody Test to Detect Coronavirus Infection
by Zacks Equity Research
Abbott (ABT) launches a lab-based serology blood test to detect the presence of antibodies post the coronavirus infection.
RMDPositive Net Change ABTPositive Net Change PAHCNegative Net Change EYEPositive Net Change
medical
QIAGEN Launches Assay for Cancer Patients Following FDA's Nod
by Zacks Equity Research
QIAGEN (QGEN) paves the way for metastatic CRC treatment in adults with the launch of an FDA-approved companion diagnostic test kit.
RMDPositive Net Change QGENNegative Net Change PAHCNegative Net Change EYEPositive Net Change
biotechs medical
NuVasive (NUVA) Posts Q1 Preliminary Results, Withdraws View
by Zacks Equity Research
A decline in elective surgical procedures due to coronavirus outbreak weighs on NuVasive's (NUVA) preliminary revenue results for first-quarter 2020.
RMDPositive Net Change NUVANegative Net Change PAHCNegative Net Change EYEPositive Net Change
medical
Are Investors Undervaluing Phibro Animal Health (PAHC) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
PAHCNegative Net Change
cheap-stocks pe-ratio undervalued-stocks valuation value-stocks
QIAGEN (QGEN) Reports Preliminary Revenue Results for Q1
by Zacks Equity Research
Investors remain optimistic with QIAGEN's (QGEN) first-quarter 2020 preliminary revenue results, which is likely to benefit from increased testing demand for coronavirus infection.
RMDPositive Net Change QGENNegative Net Change PAHCNegative Net Change EYEPositive Net Change
medical
Illumina (ILMN) Posts Q1 Preliminary Results, Withdraws View
by Zacks Equity Research
Investors remain optimistic on Illumina's (ILMN) strong preliminary revenue results for first-quarter 2020.
ILMNNegative Net Change RMDPositive Net Change PAHCNegative Net Change EYEPositive Net Change
medical
Here's Why You Should Add ResMed (RMD) in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about ResMed (RMD) on its focus on digital health technology and combatting the coronavirus outbreak.
SRDXPositive Net Change RMDPositive Net Change PAHCNegative Net Change EYEPositive Net Change
medical
Integra Releases Preliminary Q1 Results, Withdraws '20 View
by Zacks Equity Research
Integra (IART) unable to measure the magnitude of total loss it has to bear out of the coronavirus-led economic damages, and hence, withdraws the full-year guidance.
IARTPositive Net Change RMDPositive Net Change PAHCNegative Net Change EYEPositive Net Change
medical
Medtronic (MDT) Demonstrates Global Growth Amid Cost Concerns
by Zacks Equity Research
Medtronic's (MDT) international Diabetes business registers solid growth on the continued adoption of MiniMed 670G in overseas markets.
MDTPositive Net Change RMDPositive Net Change PAHCNegative Net Change EYEPositive Net Change
medical
Here's Why You Should Hold on to Thermo Fisher (TMO) for Now
by Zacks Equity Research
Investors continue to be optimistic about Thermo Fisher (TMO) on its strong segmental growth in the fourth quarter of 2019.
RMDPositive Net Change TMOPositive Net Change PAHCNegative Net Change EYEPositive Net Change
medical